Navigation Links
Saw palmetto no more effective than placebo for urinary symptoms
Date:9/27/2011

Saw palmetto, a widely used herbal dietary supplement, does not reduce urinary problems associated with prostate enlargement any better than a placebo, according to research funded by the National Institutes of Health. The study was published Sept. 28 in the Journal of the American Medical Association.

Prostate enlargement, also called benign prostatic hyperplasia (BPH), can cause frequent urination, a weak or intermittent urine stream and an inability to empty the bladder completely. More than half of men in their 60s, and up to 90 percent in their 70s and 80s, have symptoms of BPH.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Center for Complementary and Alternative Medicine (NCCAM) and the Office of Dietary Supplements (ODS) supported the study. All are part of the NIH.

According to Robert A. Star, M.D., director of the NIDDK's Division of Kidney, Urologic and Hematologic Diseases, the current study met an important need for rigorous evaluation of standard and higher doses of saw palmetto. The trial also confirmed results of the earlier NIDDK- and NCCAM-sponsored Saw Palmetto Trial for Enlarged Prostates (STEP), which found that a standard daily dose of 320 milligrams provided no greater symptom relief than placebo.

"Investigators designed the current trial to determine whether daily doses of up to 960 milligrams three times the standard daily dose -- would prove better than a placebo at improving lower urinary tract symptoms in men due to BPH," said Star. "We were disappointed to find that higher doses of saw palmetto did not improve symptoms more than placebo."

Josephine P. Briggs, M.D., director of NCCAM, added that this study further illustrates the importance of conducting research on botanical products that are used extensively by the general public.

"This was a well-designed study that addressed limitations of earlier, smaller trials i
'/>"/>

Contact: Bill Polglase
NIDDKMedia@mail.nih.gov
301-496-3583
NIH/National Institute of Diabetes and Digestive and Kidney Diseases
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Palmetto Insurance Provides Individual Health Insurance In both North and South Carolina
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Gastric Banding Most Effective for Obese Teens
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. Charging less for more effective treatments could reduce health care costs while improving health
7. Split-course palliative radiotherapy confirmed as effective treatment for advanced NSCLC
8. New drug for kidney transplant recipients effective in humans
9. Two Sepsis Treatments Look Equally Effective
10. Mammogram Plus MRI Seems Cost-Effective in High-Risk Women
11. Mammogram Plus MRI Cost-Effective in High-Risk Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed another federal ... Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . , As ... their Implanon® implants, inability to locate the implants, unsuccessful and invasive attempts at ...
(Date:7/31/2015)... ... 2015 , ... Florida Hospital Tampa has started treating select ... targeted delivery of fluids to selected sites in the peripheral vascular system. Patients ... the device that provides direct, local delivery of chemotherapy to the pancreas. This ...
(Date:7/31/2015)... ... , ... Awarded to only the Top 10 hair transplant practices in the ... latest recipients of the Center of Clinical Excellence for ARTAS Robotic Hair Transplantation ... the science of hair transplant. , Parsa Mohebi Hair Restoration is known worldwide for ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe , a ... redesigned website at Healthpointe.net. The new website will feature a sleek and streamlined ... serves to provide smoother interactions between patients and the Healthpointe clinics and ensures ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
Breaking Medicine News(10 mins):Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2
... ... been associated with numerous warnings. If YAZ®/Yasmin® side effects have resulted in ... ... -- The widely-used oral contraceptive YAZ® (alternatively named Yasmin® ) has recently been targeted ...
... 11 Emdeon Inc. (the "Company") today announced the pricing of ... common stock at a price of $15.50 per share. Of the ... were offered by selling stockholders. The shares will be listed on ... the extent that the underwriters sell more than 23,700,000 shares of ...
... , , , ... to repay more than $500 million in benefits that were unlawfully ... part of a class action settlement preliminarily approved by U.S. District ... were suspended or denied between 2000 and 2006 will be notified ...
... , LIONVILLE, Pa., Aug. 11 West ... Federici, Chief Financial Officer, and Michael Anderson, Vice President, Treasurer and Head ... Ideas" Summer Conference on Tuesday, August 18, 2009 in White Plains, NY. ... presentation or a webcast, Mr. Federici and Mr. Anderson will present a ...
... , , , ... Web site , , CHICAGO, Aug. 11 ... o to/publicsurvey and become eligible to win a ... Web site, ADA.org. , , ADA.org provides news and information ...
... , , ATLANTA, Aug. 11 Sean Carroll, CEO ... , has been appointed to serve as a board member of the ... AHI M A ). The ... 1962, is a non-profit organization that provides development, research and scholarships for ...
Cached Medicine News:Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 2Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 3Health News:Ohio Law Firm Warns of Birth Control Pill YAZ/Yasmin Side Effects Lawsuits 4Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 2Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 3Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 4Health News:Government Stops Unlawful Social Security Suspensions; Agrees to Repay More Than Half a Billion in Back Benefits 2Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2Health News:Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors 2
(Date:7/30/2015)... VANCOUVER , July 30, 2015  OncoGenex Pharmaceuticals, ... will report its second quarter 2015 financial results on ... conference call and live webcast at 4:30 p.m. Eastern ... development programs and a general corporate update. ... Investor Relations page of the OncoGenex website at ...
(Date:7/30/2015)... 30, 2015  Cleveland Clinic President Wael Barsoum ... last month that industry is compelled to adopt declining ... the efficiencies—and develop the transformational innovations -- required to ... were preceded by Doug Kohrs , past President ... who stressed that industry must add "episode of care," ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... PRINCETON, N.J., Feb. 2, 2011 Eli Lilly and ... Company (NYSE: BMY ) announced today that ... global Phase III studies evaluating necitumumab, an investigational anti-cancer ... lung cancer (NSCLC). (Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO) ...
... BOTHELL, Wash., Feb. 2, 2011 Cardiac Science Corporation ... ) and diagnostic cardiac monitoring devices, has been ... Flow Control facilities globally. Tyco Flow Control is a $3.4B ... facilities throughout the globe. The first phase of the rollout, ...
Cached Medicine Technology:Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 2Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 3Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 4Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 5Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 6Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 7Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 8Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 9Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab 10Tyco Division Awards Global AED Contract to Cardiac Science 2Tyco Division Awards Global AED Contract to Cardiac Science 3Tyco Division Awards Global AED Contract to Cardiac Science 4
PTC-100 cycler with gold/silver block with Hot Bonnet heated lid, holds one 96-well V-plate or96x0.2ml tubes...
MBS 0.2 ml satellite block unit with height adjusting heated lid, 96 well standard block - holds 96 x 0.2ml tubes or 1 x 96 well plate (includes tube thermistor)...
PxE thermal Cycler. 0.2ml, 96 well block holds 96 tubes or 1 x 96 well plate. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User f...
... (PxE) is a licensed 96 well PCR machine, ... for money thermal cycling. It is built ... in manufacturing and retains a high level of ... products in the range. The combination of ...
Medicine Products: